Drug class
Antithrombin-directed small interfering RNA (siRNA); RNA interference haemostatic therapy
Mechanism of action
A GalNAc-conjugated siRNA is taken up by hepatocytes and directs RNA-induced silencing complex-mediated degradation of antithrombin mRNA, reducing antithrombin protein and increasing thrombin generation to improve haemostasis.
General use cases
- Routine prophylaxis to prevent or reduce bleeding episodes in adults and paediatric patients aged 12 years and older with haemophilia A or B, with or without factor VIII or IX inhibitors, under the US QFITLIA indication; subcutaneous dosing is monitored using antithrombin activity
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
